PD Frontline Study and Upcoming Parkinson’s Research Opportunities

At the end of the year, we are receiving many updates and summaries. One that caught my attention is PD Frontline. PD Frontline is a UK initiative placing people with Parkinson’s at the heart of research by enabling genetic testing for two key risk factors, LRRK2 and GBA, through a simple online and postal process—paving the way for clinical trials of potential disease-slowing drugs. As of December 2024, the PD Frontline study has enrolled nearly 6,200 participants, making it the largest research initiative of its kind for Parkinson’s Disease (PD). The study spans across the UK with contributions from 31 NHS Trust sites, ensuring a diverse pool of participants that mirrors the broader Parkinson’s community. This large-scale collaboration plays a vital role in advancing PD research. Key Updates in Parkinson’s Research ASPro-PD Trial The much-anticipated ASPro-PD trial, exploring the potential of Ambroxol as a treatment for Parkinson’s, is set to launch in early 2025. Over a two-year period, 330 participants will be recruited across 15 NHS sites in England, Wales, and Scotland. The trial will also include an optional sub-study investigating cerebrospinal fluid to deepen understanding of the disease’s mechanisms. EJS-ACT PD Study This innovative trial will test multiple treatments simultaneously for Parkinson’s. It aims to enroll 1,600 participants over three years, offering flexibility for participation from home and through 40 NHS sites. The study includes advanced investigations like MRI scans and genetic sampling. RAPSODI Study Focused on early or preclinical symptoms of PD, RAPSODI invites individuals with genetic links to PD (such as GBA1 mutations) and their relatives for screening and various diagnostic tests. Microbiome Study This research examines the connection between the gut microbiome and PD, specifically in individuals with GBA1 mutations. Participants provide biological samples for analysis, contributing to the understanding of gut health in Parkinson’s. Denmark Study A collaboration with Danish researchers explores whether PD begins in the brain or the body. This study includes advanced imaging and sample collection at Aarhus University Hospital, with all travel and accommodation costs covered for participants and one companion. GP2 Project Part of the global effort to enhance genetic research in Parkinson’s, GP2 collects samples and data to better understand the genetic factors contributing to the disease. The program is particularly committed to including diverse, underrepresented populations. Staying Involved Participants can stay updated through PD Frontline’s social media channels, where they’ll find trial updates, publications, and community news. For more information, visit @pdfrontline or contact them directly at 020 8016 8413 or pdfrontline@ucl.ac.uk. The dedication of participants and researchers alike ensures that each study moves closer to breakthroughs in understanding and treating Parkinson’s Disease.